ARQT (Arcutis Biotherapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ARQT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Patrick Burnett | See Remarks | Sell | — | — |
| 2026-08-05 | Todd Watanabe | See Remarks | Sell | — | — |
| 2026-08-05 | Masaru Matsuda | See Remarks | Sell | — | — |
| 2026-07-17 | Christopher Peetz | Director | A | — | — |
| 2026-07-17 | Howard G. Welgus | Director | MIXED | — | — |
| 2026-06-17 | SUE-JEAN LIN | Director | Sell | — | — |
| 2026-06-17 | Howard G. Welgus | Director | MIXED | — | — |
| 2026-06-12 | Patrick J Heron | Director | — | — | — |
| 2026-06-09 | Patrick J Heron | Director | A | — | — |
| 2026-06-09 | Amit Munshi | Director | A | — | — |
| 2026-06-09 | Keith R Leonard | Director | A | — | — |
| 2026-06-09 | Howard G. Welgus | Director | A | — | — |
| 2026-06-09 | Neha Krishnamohan | Director | A | — | — |
| 2026-06-09 | Halley E Gilbert | Director | A | — | — |
| 2026-06-09 | Terrie Curran | Director | A | — | — |
| 2026-06-09 | SUE-JEAN LIN | Director | A | — | — |
| 2026-05-13 | Latha Vairavan | SVP Chief Financial Officer | Sell | — | — |
| 2026-05-13 | Patrick Burnett | See Remarks | Sell | — | — |
| 2026-05-06 | Masaru Matsuda | See Remarks | Sell | — | — |
| 2026-05-06 | Latha Vairavan | SVP Chief Financial Officer | Sell | — | — |
| 2026-05-06 | Patrick Burnett | See Remarks | Sell | — | — |
| 2026-05-06 | Todd Watanabe | See Remarks | Sell | — | — |
| 2026-05-05 | Howard G. Welgus | Director | Sell | — | — |
| 2026-04-03 | Howard G. Welgus | Director | Sell | — | — |
| 2026-03-04 | Howard G. Welgus | Director | Sell | — | — |
| 2026-03-04 | Keith R Leonard | Director | MIXED | — | — |
| 2026-03-03 | Larry Todd Edwards | See Remarks | MIXED | — | — |
| 2026-03-03 | Latha Vairavan | SVP Chief Financial Officer | MIXED | — | — |
| 2026-03-03 | Todd Watanabe | See Remarks | MIXED | — | — |
| 2026-03-03 | Masaru Matsuda | See Remarks | MIXED | — | — |
| 2026-03-03 | Patrick Burnett | See Remarks | MIXED | — | — |
| 2026-02-04 | Howard G. Welgus | Director | Sell | — | — |
| 2026-02-04 | Patrick Burnett | See Remarks | Sell | — | — |
| 2026-02-04 | Latha Vairavan | SVP Chief Financial Officer | Sell | — | — |
| 2026-02-04 | Todd Watanabe | See Remarks | Sell | — | — |
| 2026-02-04 | Larry Todd Edwards | See Remarks | Sell | — | — |
| 2026-02-04 | Masaru Matsuda | See Remarks | Sell | — | — |
| 2026-01-07 | Patrick Burnett | See Remarks | Sell | — | — |
| 2026-01-06 | Howard G. Welgus | Director | Sell | — | — |
| 2026-01-02 | Patrick Burnett | See Remarks | Sell | — | — |
| 2025-12-17 | Patrick Burnett | See Remarks | MIXED | — | — |
| 2025-12-08 | Amit Munshi | Director | A | — | — |
| 2025-12-03 | Masaru Matsuda | See Remarks | Sell | — | — |
| 2025-12-03 | Howard G. Welgus | Director | Sell | — | — |
| 2025-11-25 | SUE-JEAN LIN | Director | MIXED | — | — |
| 2025-11-24 | Todd Watanabe | See Remarks | Sell | — | — |
| 2025-11-21 | Masaru Matsuda | See Remarks | Sell | — | — |
| 2025-11-21 | Halley E Gilbert | Director | MIXED | — | — |
| 2025-11-17 | Keith R Leonard | Director | G | — | — |
| 2025-11-17 | Neha Krishnamohan | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,783,613 | — |
| — | 10%+ Owner | 8,445,498 | — |
| — | Director | 4,267,564 | — |
| — | 10%+ Owner | 3,937,764 | — |
| — | Director | 3,534,537 | — |
| — | 10%+ Owner | 2,825,602 | — |
| — | Director | 917,807 | — |
| — | See Remarks | 746,165 | — |
| — | Chief Technical Officer | 331,332 | — |
| — | Director | 191,815 | — |
| — | Chief Financial Officer | 182,774 | — |
| — | See Remarks | 175,281 | — |
| — | SVP and Chief Business Officer | 145,505 | — |
| — | Chief Financial Officer | 144,185 | — |
| — | See Remarks | 127,573 | — |
| — | See Remarks | 120,244 | — |
| — | SVP Chief Financial Officer | 85,978 | — |
| — | Director | 66,830 | — |
| — | Chief Commercial Officer | 63,429 | — |
| — | SVP, Operations | 62,862 | — |
| — | Director | 59,661 | — |
| — | Chief Financial Officer | 59,115 | — |
| — | Director | 29,651 | — |
| — | Director | 27,901 | — |
| — | Director | 27,901 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARQT quote page; the site-wide leaderboard is on the insider transactions hub.